COLI-URINAL EFFERVECENT

Indications

Approved Uses

Symptomatic relief of urinary tract spasm/colic and adjunct urinary antisepsis in lower urinary tract infections where methenamine is appropriate; it is not an approved anthelmintic indication based on the verified API data provided.

Dosage & Administration

Dose Adjustment Notes

Avoid/contraindicated in severe renal impairment and in severe hepatic impairment; use caution and consider dose/interval adjustment in mild-moderate renal impairment and in older adults due to reduced renal clearance and higher risk of adverse effects.

Safety & Warnings

Contraindications

Hypersensitivity to any component; severe renal impairment; severe hepatic impairment; severe dehydration; metabolic acidosis; concomitant sulfonamides (avoid/contraindicated due to crystalluria risk with methenamine); seizure disorders/epilepsy (avoid due to piperazine neurotoxicity).

Warnings & Precautions

Ensure urine is acidic for methenamine efficacy (avoid alkalinizing agents); avoid concomitant sulfonamides; maintain adequate hydration; use caution/avoid in renal impairment and in seizure disorders; not appropriate as sole therapy for acute febrile/systemic UTI-seek evaluation if fever/flank pain occurs.

Age Restriction

Pediatric use only under physician supervision; avoid routine use in young children unless specifically prescribed.

Drug Interactions

Interaction Severity

MAJOR/CONTRAINDICATED: Sulfonamides (risk of crystalluria/precipitation with formaldehyde). MODERATE: Urinary alkalinizers (e.g., potassium/sodium citrate, bicarbonate, acetazolamide) reduce methenamine efficacy. CAUTION: Drugs lowering seizure threshold (including phenothiazines/antipsychotics) may increase neurotoxicity risk with piperazine.

Food Interaction

May be taken with food to reduce gastrointestinal upset; avoid agents that alkalinize urine (e.g., sodium bicarbonate/citrate preparations, some antacids) because higher urinary pH reduces methenamine activation.

Special Populations

Kidney Impairment

Contraindicated/avoid in severe renal impairment (e.g., CrCl <30 mL/min); use with caution in mild-to-moderate impairment with close monitoring.

Storage & Patient Advice

Patient Counseling

Dissolve the measured dose fully in water and drink immediately; take after meals if stomach upset occurs; drink plenty of fluids; avoid urinary alkalinizers/antacids/citrate preparations that raise urine pH; do not take with sulfonamide antibiotics; seek care for rash, severe dysuria/hematuria, or neurologic symptoms (e.g., dizziness, tremor, seizures); store below 25°C.

Monitoring Requirements

Monitor urinary pH (target acidic urine, typically <6) and clinical response; consider periodic renal function in at-risk patients and urine cultures if recurrent infection is being suppressed or symptoms persist.

Pharmacology

Bioavailability

Methenamine: readily absorbed after oral administration; clinically meaningful conversion to formaldehyde occurs mainly in acidic urine (not in the GI tract). Piperazine: rapidly absorbed orally. Khellin: absorbed orally but human bioavailability is not well characterized in modern references.

Metabolism

Methenamine: not significantly metabolized systemically; hydrolyzes in acidic urine to formaldehyde and ammonia. Piperazine: minimal to partial hepatic metabolism with predominant renal elimination. Khellin: hepatic metabolism (extent and pathways variably described).

Excretion

Methenamine: primarily renal excretion, largely unchanged, with urinary conversion to formaldehyde/ammonia in acidic urine; a substantial fraction (commonly cited ~70-90%) is recovered in urine within 24 hours. Piperazine: primarily excreted in urine. Khellin: eliminated via hepatic metabolism with excretion in bile and urine (exact proportions not well defined).

Protein Binding

Methenamine: low/negligible protein binding. Piperazine: not well characterized (generally considered low/unknown). Khellin: not well characterized (unknown).

Product Information

Generic Availability

Yes

Urological Condition

UTI, Kidney Stones

Legal Disclaimer - Al Mujtama Pharmacy The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment. Al Mujtama Pharmacy assumes no legal or medical liability for: Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist Any discrepancy between the information provided and the product's package insert or SFDA guidelines Any misuse of medication resulting from personal interpretation of the content displayed Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication. By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation. Your health is a trust - always consult your doctor first.